- Conditions
- Aging, Functional Decline
- Interventions
- Dapagliflozin 10Mg Oral Tablet, Semaglutide oral, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2031
- U.S. locations
- 5
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 3,937
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 445
- States / cities
- Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more
- Conditions
- Colorectal Cancer Screening
- Interventions
- PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG, Metoclopramide, Erythromycin, SUPREP oral sulfate solution, Bisacodyl, SUPREP oral sulfate solution with Gastrografin
- Device · Drug
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more
- Conditions
- HIV Infection, HIV Infections
- Interventions
- Adherence report
- Behavioral
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Wound Closure, Dehisced Surgical Wounds
- Interventions
- Evaluating wound closure products to close larger surgical site incisions, Evaluating wound closure products to close smaller surgical site incisions
- Device
- Lead sponsor
- Medline Industries
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Johnstown, Colorado
- Conditions
- High Risk for Falling
- Interventions
- PUP™ sock
- Device
- Lead sponsor
- Tammy Moore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 521 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hospitalization
- Interventions
- Care Transitions Innovation (C-TraIn)
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Renal Transplant
- Interventions
- Arm 1 Everolimus/Reduced dose tacrolimus
- Drug
- Lead sponsor
- University of Toledo Health Science Campus
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Alcoholism
- Interventions
- Naltrexone, placebo, Medication Management (MM), Combined Behavioral Intervention (CBI), Telephone Counseling
- Drug · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Tobacco Dependence
- Interventions
- Innovative System, Standard Treatment Control (STC)
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diabetes, Cardiovascular Disease
- Interventions
- Diabetes Self-Management Education
- Behavioral
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Nail Diseases, Nail Abnormality
- Interventions
- Hydrocodone 5Mg/Acetaminophen 325Mg Tab, Acetaminophen 1000mg, Ibuprofen 400 mg
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer
- Interventions
- everolimus, antiangiogenesis therapy, biopsy, diagnostic procedure, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis, protein tyrosine kinase inhibitor therapy, reverse transcriptase-polymerase chain reaction
- Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib
- Procedure · Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Portland, Oregon • Dallas, Texas
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration
- Procedure · Radiation · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 44
- States / cities
- Duarte, California • Irvine, California • Orange, California + 35 more
- Conditions
- Primary Care
- Interventions
- Relational Agent ( RA) Alex
- Behavioral
- Lead sponsor
- Anita Y. Kinney, PhD, RN
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Breast Cancer
- Interventions
- AEZS-108, SCCC, Dexamethasone
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
- Interventions
- Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
- Device · Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 23
- States / cities
- Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
- Conditions
- Opioid-Related Disorders, Substance-Related Disorders
- Interventions
- oxycodone 15 mg, oxycodone 30 mg, Placebo 0 mg
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
- Interventions
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 28 Days and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Opioid-use Disorder, Medication Assisted Treatment, Substance Use Disorders
- Interventions
- Mindfulness based relapse prevention and peer mentoring
- Behavioral
- Lead sponsor
- University of Alabama, Tuscaloosa
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Homewood, Alabama
- Conditions
- Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
- Interventions
- Dexmedetomidine, 0.9% Saline
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Interstitial Cystitis
- Interventions
- Not listed
- Lead sponsor
- CAMC Health System
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Charleston, West Virginia
- Conditions
- Mild Cognitive Impairment (MCI), Amyloid Pathology
- Interventions
- Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation
- Device
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma